Stryker (NYSE:SYK) Releases Quarterly Earnings Results, Beats Expectations By $0.20 EPS

Stryker (NYSE:SYK) issued its quarterly earnings results on Thursday. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20, Zacks reports. Stryker had a net margin of 14.43% and a return on equity of 24.06%. The business had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. During the same period in the previous year, the business posted $3.13 earnings per share. The business’s revenue was up 9.4% compared to the same quarter last year. Stryker updated its FY 2026 guidance to 14.950-15.100 EPS.

Here are the key takeaways from Stryker’s conference call:

• Organic sales grew 9% in Q2, with high-single-digit growth in both MedSurg and Neurotechnology and Orthopaedics, while adjusted EPS increased 17.9% to $3.69.
• Strong demand for capital equipment produced an elevated backlog, and Stryker expects production recovery and fulfillment of orders to support a stronger second half.
• Mako installations reached a quarterly record, with rising utilization and the full U.S. launch of handheld Mako RPS adding to the company’s robotics growth opportunity; several other product launches also received positive customer feedback.
• Peripheral Vascular sales were hurt by a supply disruption at an Inari manufacturing plant, creating significant backorders and lost sales; the company expects improvement but said growth will take time to rebuild.
• Stryker narrowed 2026 guidance to 8.3%-9.3% organic sales growth and adjusted EPS of $14.95-$15.10, citing cybersecurity-related remediation and manufacturing costs despite improved margins and a planned resumption of share repurchases.

Stryker Stock Performance

Shares of Stryker stock traded down $21.63 on Friday, reaching $326.41. 4,535,844 shares of the company were exchanged, compared to its average volume of 2,249,660. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The firm has a market cap of $125.13 billion, a price-to-earnings ratio of 33.82, a P/E/G ratio of 2.23 and a beta of 0.77. Stryker has a 1-year low of $281.00 and a 1-year high of $401.99. The company’s 50-day moving average is $317.28 and its two-hundred day moving average is $334.92.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th were issued a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, June 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s dividend payout ratio is 40.74%.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Leerink Partners cut their price target on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a report on Friday, June 5th. Truist Financial lifted their target price on shares of Stryker from $330.00 to $340.00 and gave the stock a “hold” rating in a research note on Friday. Citigroup dropped their price target on shares of Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research report on Tuesday, April 7th. Sanford C. Bernstein set a $410.00 price objective on Stryker in a research note on Friday, May 1st. Finally, Wells Fargo & Company decreased their target price on Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $387.88.

Key Stories Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker reported second-quarter revenue of $6.59 billion, up 9.4% year over year, while adjusted EPS of $3.69 exceeded consensus estimates. Organic sales growth reached 9%, supported by strong demand for orthopedic, spinal and other medical devices. Stryker beats quarterly estimates on strong demand for medical devices
• Positive Sentiment: Management said it has regained momentum following the cyber disruption and resumed share repurchases. Its full-year guidance calls for 8.3% to 9.3% organic sales growth and adjusted EPS of $14.95 to $15.10. Stryker expects 2026 organic sales growth and adjusted EPS
• Positive Sentiment: JPMorgan maintained an “overweight” rating, although it reduced its price target to $350. Truist raised its target to $340 while retaining a “hold” rating, and BTIG continues to rate the shares “buy.”
• Neutral Sentiment: The updated guidance was narrower but remained broadly close to prior expectations and analyst forecasts. This suggests operational stability, but not a major upside revision that could drive a stronger investor reaction.
• Neutral Sentiment: Analyst opinion remains generally constructive, with no recent sell ratings cited and a six-month median price target of $385, though target reductions indicate some caution regarding valuation or near-term upside.
• Negative Sentiment: The main pressure on SYK appears to be an expectations reset: despite the earnings beat, investors had anticipated a more substantial increase to full-year guidance after the cyberattack recovery. SYK falls despite Q2 earnings beat
• Negative Sentiment: Reported insider activity has been heavily weighted toward selling, with no purchases and substantial sales over the past six months. This may add to investor concerns about valuation and management confidence, although the trades do not necessarily reflect current operating performance.

Insider Buying and Selling at Stryker

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the transaction, the vice president owned 13,137 shares in the company, valued at approximately $3,728,937.45. This represents a 28.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 323,264 shares of company stock valued at $100,659,489 in the last ninety days. Company insiders own 4.60% of the company’s stock.

Institutional Investors Weigh In On Stryker

Institutional investors and hedge funds have recently bought and sold shares of the business. Brighton Jones LLC boosted its holdings in shares of Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after buying an additional 609 shares during the period. Schnieders Capital Management LLC. acquired a new stake in shares of Stryker in the second quarter worth about $205,000. Marshall Wace LLP grew its holdings in Stryker by 107.9% during the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after purchasing an additional 77,831 shares during the last quarter. Nebula Research & Development LLC acquired a new position in Stryker during the 2nd quarter worth $219,000. Finally, HUB Investment Partners LLC acquired a new stake in Stryker in the 2nd quarter valued at approximately $253,000. 77.09% of the stock is owned by institutional investors and hedge funds.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.